Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Similar documents
Erythropoiesis Stimulation and Heart Failure: Current Status

Supplementary Appendix

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

egfr > 50 (n = 13,916)

Predicting and changing the future for people with CKD

SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics

Disclosures for Presenter

Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Anemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care

Managing Chronic Kidney Disease: Reducing Risk for CKD Progression

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Supplementary Appendix

Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia

Biomarkers in the Assessment of Congestive Heart Failure

AHA Nov 18, 2013 Late Breaking Session

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria

HFpEF, Mito or Realidad?

UPDATES IN MANAGEMENT OF HF

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

Individual Study Table Referring to Part of Dossier: Volume: Page:

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

Antihypertensive Trial Design ALLHAT

CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

Cardiovascular Risk Reduction in Kidney Transplant Recipients

Blood Pressure Monitoring in Chronic Kidney Disease

Product: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1

Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial

Iron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

The earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College

CVD risk assessment using risk scores in primary and secondary prevention

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease

CKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College

Copeptin in heart failure: Associations with clinical characteristics and prognosis

Launch Meeting 3 rd April 2014, Lucas House, Birmingham

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Metabolic Syndrome and Chronic Kidney Disease

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

The ACC Heart Failure Guidelines

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Published trials point to a detrimental relationship

LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

Cardiovascular Diseases in CKD

Decline in CV-Mortality

ANEMIA & HEMODIALYSIS

4.1.1: We recommend that all people with CKD be considered at increased risk for cardiovascular disease. (1A) 4.1 CKD and CVD

Diabetes and the Heart

CKD & HT. Anne-Marie Angus

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Office Management of Reduced GFR Practical advice for the management of CKD

Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

The Diabetes Link to Heart Disease

DECLARATION OF CONFLICT OF INTEREST

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Systolic Blood Pressure Intervention Trial (SPRINT)

Iron deficiency in heart failure

Selective Cardiac Myosin Activators in Heart Failure

The Clinical Unmet need in the patient with Diabetes and ACS

surtout qui n est PAS à risque?

Lowering blood pressure (BP) in patients with type 2

Epogen / Procrit. Epogen / Procrit (epoetin alfa) Description

The Latest Generation of Clinical

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Effect of Saxagliptin on Renal Outcomes in the SAVOR TIMI- 53 study- Appendixes:

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas

Chapter Two Renal function measures in the adolescent NHANES population

Supplementary Online Content

Drugs acting on the reninangiotensin-aldosterone

RED CELL DISTRIBUTION WIDTH

Correlation of novel cardiac marker

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2

Review of guidelines for management of dyslipidemia in diabetic patients

Circulating Galectin-3 as a Prognostic. Biomarker in Patients with Chronic. Lymphocytic Leukemia

Bardoxolone Methyl Prevents egfr Decline in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes Post-hoc Analyses from BEACON

SUPPLEMENTAL MATERIAL

Improving Diagnostic, Prognostic & Therapeutic Biomarkers in Heart Disease. Professor Mark Richards Medicine, University of Otago, Christchurch

DECLARATION OF CONFLICT OF INTEREST

T. Suithichaiyakul Cardiomed Chula

Clinical Controversies in Perioperative Medicine

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

KEEP 2.0 Annual Data Report Chapter Five

KDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4

Transcription:

Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis, Janet B. McGill, Patrick Parfrey, Hans- Henrik Parving, Robert M Toto, Scott D. Solomon & Marc A. Pfeffer for the TREAT investigators* *darbepoetin alfa Disclosures: This study was sponsored by Amgen. All investigators received research funding and some received consulting fees from the sponsor. A full list of disclosures is publicly released.

Outline of presentation The clinical problem Summary of TREAT Cardiovascular risk modelling- standard variables Cardiovascular risk modelling- addition of cardiac biomarkers Discussion and conclusions

Survival Probability (All-Cause Mortality) Incremental Risk of CKD and Anaemia in relation to Mortality in Subjects With Diabetes 1.0 ARIC, Cardiovascular Health Study, Framingham Heart Studies. n = 3015 subjects with DM.90.80.70 DM DM, Anaemia DM, CKD.60.50 Hypothesis Anemia+, CKD+, (71) HR: 2.84 (2.05 to 3.91) Anemia+, CKD-, (174) HR: 1.21 (0.89 to 1.65) Anemia-, CKD+, (344) HR: 1.51 (1.25 to 1.82) Anemia-, CKD-, (2426) HR: 1 In patients with type 2 diabetes, chronic kidney disease not requiring dialysis, and concomitant anaemia, raising haemoglobin with darbepoetin alfa would lower the rates of death and cardiovascular morbidity and/or death and end-stage renal disease..20.10 0 0 2 4 6 8 10 Years Since Baseline Vlagopoulos PT et al. J Am Soc Nephrol 16: 3403 3410, 2005 DM, CKD, Anaemia

TREAT: Trial to Reduce Cardiovascular Events with Aranesp (Darbepoetin alfa) Therapy International (24) multi-centre (623), double-blind, placebo-controlled randomized trial Study Population Type 2 DM CKD egfr 20-60 L/min/1.73 m 2 Anaemia Hb 11 g/dl transferrin saturation 15% N = 2012 Darbepoetin Group (Target Hemoglobin 13 g/dl) randomized (1:1), double blind, placebo-controlled N = 2026 Placebo Group Event-driven: 1203 patients with events 2 composite primary endpoints (adjudicated): Cardiovascular : death, MI, myocardial ischaemia, CHF or stroke. Renal: death or ESRD.

Baseline Characteristics Variable Darbepoetin alfa N = 2012 Placebo N = 2026 P-value Age (years) 68 68 0.22 Women 58.5 56.0 0.10 BMI (kg/m 2 ) 30.5 30.1 0.11 CVD history 64.0 66.9 0.05 CAD 43.2 45.5 0.16 Heart failure 31.5 35.2 0.01 Myocardial infarction 18.4 18.3 0.95 Stroke 11.5 10.7 0.41 PAD 21.2 20.8 0.73 Systolic BP (mmhg) 136 135 0.25 Diastolic BP (mmhg) 71 70 0.55 LDL mmol/l (mg/dl) 2.2 (84) 2.2 (85) 0.41

Baseline Characteristics Variables Darbepoetin alfa N = 2012 Placebo N = 2026 P-value Serum creatinine µmol/l (mg/dl) 159 (1.8) 168 (1.9) 0.01 egfr (ml/min/1.73 m 2 ) 34 33 0.03 Protein to creatinine ratio (g/g creatinine) 0.4 0.4 0.73 Hemoglobin A1c (%) 7.0 6.9 0.02 Baseline Hb (g/dl) 10.5 10.4 0.15 Insulin % 48.7 49.8 0.49 Oral hypoglycemic agents % 57.5 56.1 0.36 ACE inhibitor or ARB % 79.7 80.0 0.82 Beta blocker % 49.9 48.7 0.43 Statin or other lipid lowering % 64.6 64.0 0.72 Aspirin or other antiplatelet % 48.0 48.6 0.68

Patients With Events (%) Primary CV endpoint: Death, MI, Myocardial Ischemia,HF, Stroke 50 Median 2.4 yr follow-up 40 Darbepoetin alfa 632 (31.4%) Placebo 602 (29.7%) 30 20 HR: 1.05 (0.94-1.17) P = 0.41 10 0 Hb Median: 10.6 IQR [9.9 11.3] Hb Median: 12.5 IQR [12.0 12.8] 0 6 12 18 24 30 36 42 48 Months

Primary Composite and Component Endpoints Endpoint Darbepoetin alfa N = 2012 Placebo N = 2026 HR (95% CI) P- value CV Composite 632 (31.4) 602 (29.7) 1.05 (0.94-1.17) 0.41 Death 412 (20.5) 395 (19.5) 1.05 (0.92-1.21) 0.48 Heart Failure 205 (10.2) 229 (11.3) 0.89 (0.74-1.08) 0.24 MI 124 (6.2) 129 (6.4) 0.96 (0.75-1.22) 0.73 Stroke 101 (5.0) 53 (2.6) 1.92 (1.38-2.68) <0.001 Myocardial Ischaemia 41 (2.0) 49 (2.4) 0.84 (0.55-1.27) 0.40 Renal Composite 652 (32.4) 618 (30.5) 1.06 (0.95-1.19) 0.29 ESRD 338 (16.8) 330 (16.3) 1.02 (0.87-1.18) 0.83

TREAT: Trial conclusions In patients with Type 2 DM, CKD and anaemia a strategy to treat anemia with darbepoetin alfa: 1 : Did not reduce either primary composite endpoint of: Death and CV events or Death and ESRD Reduced RBC transfusion (24.5% vs. 14.8%. HR:0.56 (0.49-0.65) P < 0.001) Fact-Fatigue modestly improved Higher stroke rates were documented Supports data from cancer studies of higher mortality For many, these risks will outweigh the rather modest potential benefits

Outline of presentation The clinical problem Summary of TREAT Cardiovascular risk modelling- standard variables Cardiovascular risk modelling- addition of cardiac biomarkers Discussion and conclusions

Cardiovascular risk modelling standard variables Post-hoc composite outcome of cardiovascular death myocardial infarction, stroke or hospitalization for heart failure or myocardial ischaemia Univariate analysis of candidate variables Step 1: Individual multivariable models using age, sex, race in each and related candidate variables e.g. diabetes complications Step 2: Final multivariable model including predictors from Step1plus egfr, BP, HR and randomized treatment (darbepoetin/placebo).

Patients With Events (%) CV death, MI, myocardial ischaemia, HF or stroke 50 Median 2.4 yr follow-up 40 Darbepoetin alfa 518 (25.7%) Placebo 492 (24.3%) 30 20 10 HR: 1.04 (0.92-1.18) P = 0.54 0 0 12 24 36 48 Months

Baseline variables included in models variables not predictive Demographics/exam. Age Sex Smoking history HR BP BMI History Coronary heart disease Cerberovascular disease Heart failure Arrhythmia (AF/VT/VF/ICD/PM) PAD Hypertension Diabetes complications Lung disease GI bleeding Blood transfusion Gout/hyperuricaemia Treatment Insulin Loop diuretic Haematology/iron indices Hb Reticulocytes Ferritin TSAT WBC Platelets Blood chemistry TC/LDL/TG Potassium GFR (MDRD estimated) BUN Albumin CRP (not hscrp) HbA1c Urine Protein/creatinine ratio ECG (Echocardiogram)

Predictive model for CV mortality and morbidity ranked by chi-square ( 2 ) Variable (category/per unit increase) HR (95% CI) 2 P-value Heart failure (yes) 1.74 (1.51-2.01) 55.8 <.0001 Age (year) 1.03 (1.02-1.04) 46.1 <.0001 Urine prot/cr ratio (log g/g) 1.19 (1.13-1.26) 39.2 <.0001 CRP (g/dl) >6.6 >3.0-6.6 1.44 (1.23-1.69) 1.20 (1.02-1.41) 20.6 4.6 <.0001.0312 Abnormal ECG (yes) 1.42 (1.21-1.66) 19.2 <.0001 Albumin (g/dl) 0.70 (0.59-0.83) 16.7 <.0001 Coronary heart disease (yes) 1.32 (1.15-1.52) 15.0.0001 Cardiac arrhythmia (yes) 1.33 (1.13-1.56) 11.9.0006 Haemoglobin A1c (%) 1.07 (1.02-1.12) 8.2.0042 Reticulocytes (%) 1.11 (1.03-1.20) 7.8.0053 BUN (mg/dl) 1.06 (1.01-1.11) 5.8.0164 Insulin (yes) 1.22 (1.06-1.40) 7.3.0068 Cerebrovascular disease (yes) 1.21 (1.03-1.41) 5.5.0192 Loop diuretic (yes) 1.18 (1.02-1.37) 4.6.0312 Male 1.16 (1.01-1.34) 4.3.0381 Race (other vs. white) (black vs. white) 0.80 (0.65-0.99) 0.92 (0.77-1.09) 4.2 1.0.0417.3303

Additional prognostic information from combining urinary protein/cr ratio and CRP Adjusted HR* Cardiovascular mortality and morbidity 3 2.5 2 1.5 1 0.5 0 5.7% 20.2% <3.0 3.0-6.6 >6.6 T1 T2 T3 UPCR CRP *Age, sex, race, history CVD, abnormal ECG, HbA1c, egfr, BUN, serum albumin, retics, insulin Tx, loop diuretic Tx

Outline of presentation The clinical problem Summary of TREAT Cardiovascular risk modelling- standard variables Cardiovascular risk modelling- addition of cardiac biomarkers Discussion and conclusions

Cardiovascular risk modelling cardiac biomarker cohort First 1000 patients enrolled in TREAT had a baseline measurement of plasma cardiac biomarkers Troponin T (Roche; 99% upper reference limit 0.010 ng/ml) N terminal-pro B-type natriuretic peptide (Roche; pg/ml) Best CV risk model (developed using standard variables) was run in cardiac biomarker cohort This model was the re-run with NT-pro BNP (as log concentration) and TnT (3 categories undetectable, detectable median [0.028ng/mL] and detectable >median) added

Number of Patients NT-proBNP, TREAT baseline (n=1000) NT-proBNP Q1 Q2 Q3 Q4 < 273 pg/ml 273-601 pg/ml 602-1521 pg/ml > 1521 pg/ml 60% 450 pg/ml 38% 900 pg/ml 100 1000 10000 100000 NT-proBNP (logarithmic scale)

Troponin T, TREAT baseline (n=1000) 45% detectable TnT (>0.01ng/mL) Median detectable TnT = 0.028 ng/ml 0.01 0.02 0.04 0.06 0.08 0.10 ng/ml

CV risk model in cardiac biomarker cohort model with biomarkers Variable (category/per unit increase) HR (95% CI) 2 NT probnp (log pg/ml) 1.30 (1.15-1.46) 18.3 Age (yr) 1.03 (1.01-1.04) 16.1 Heart Failure (yes) 1.54 (1.19-2.00) 10.5 CRP (g/dl) + >6.6 >3.0-6.6 1.65 (1.22-2.23) 1.55 (1.16-2.08) 10.4 8.7 Abnormal ECG (yes) 1.45 (1.09-1.92) 6.5 Smoking (vs. current) former never TnT (ng/ml) + > 0.028 (median) 0.028 0.67 (0.41-1.09) 0.55 (0.33-0.91) 1.50 (1.06-2.13) 1.42 (1.05-1.93) 2.6 5.3 5.2 5.4 Urine prot/cr ratio (log g/g) 1.13 (1.02-1.25) 5.2

Additional prognostic information from combining NT-pro BNP and TnT Adjusted HR* Cardiovascular mortality and morbidity 3 2.5 2 1.5 1 0.5 0 4.7% <0.01 0.01-0.028 >0.028 T1 TnT 30.2% *Age, sex, race, history CVD, abnormal ECG, HbA1c, egfr, BUN, serum albumin, retics, insulin Tx, loop diuretic Tx and CRP + UPCR T2 T3 NT- BNP

Conclusions from CV risk modelling In this population with the triad of type-2 DM, CKD and anaemia, many conventional risk factors were not predictive of CV events e.g. lipids, blood pressure CRP and urinary protein/creatinine ratio were independent predictors of CV outcome This ambulatory population also had markedly abnormal cardiac biomarkers NT-pro BNP and TnT added important prognostic information to conventional risk markers In addition to aiding risk stratification, these plasma and urinary biomarkers may help understanding of the mechanisms underlying cardiac risk and suggest new therapeutic strategies in this population.